刘 军 | 博士 | 教授 | 博士生导师 | ||||||
科室: | 药物化学 | ||||||||
电子邮箱: | jliu1102@ouc.edu.cn | ||||||||
联系地址: | 山东省青岛市香港东路23号350vip8888新葡的京集团浮山校区 266071 | ||||||||
研究方向: | 1. 1. 新型靶向药物开发及临床前评价 2. 2. 基于微生物的疾病治疗研究 | ||||||||
个人简介 | | | | | |||||
刘军,医学博士、教授、硕士/博士生导师,入选350vip8888新葡的京集团青年英才第一层次,教育部第一批博后引才专项获得者,泰山学者青年专家,山东省优青。主要从事基于天然产物骨架的新型药物开发以及提高药物靶向性及成药性的药物递送研究,开发得到了多个具有临床转化潜力的小分子候选药物。发表高水平学术论文近20篇,其中第一作者或共同一作13篇,包括Science Advances, Nature Communications, Advanced Science, Nano Today, Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, Bioorganic Chemistry, Frontiers in Bioengineering and Biotechnology及ACS Medicinal Chemistry Letters等;申请专利8项,包括4项国内发明专利、2项国际发明专利和2项美国发明专利,其中授权5项;主持教育部博后引才专项、国家自然科学基金面上项目、国家自然科学基金青年基金、泰山学者青年专家、山东省优秀青年科学基金以及山东省自然科学基金博士基金等项目,参与多项国家自然科学基金面上项目及国家重大新药创制基金;担任Frontiers in Bioengineering and Biotechnology杂志Topic Coordinator, Journal of Nanobiotechnology及Journal of Medicinal Chemistry等杂志审稿人。 | |||||||||
教育背景 | | | | | |||||
2014-2018 | 山东大学 | 微生物与生化药学 | 博士 | ||||||
2011-2014 | 山东省医学科学院 | 药理学 | 硕士 | ||||||
2005-2009 | 长春工业大学 | 制药工程 | 学士 | ||||||
工作经历 | | | | | |||||
2023-至今 | 350vip8888新葡的京集团 | 教授 | | ||||||
2020-2022 | 美国威斯康星大学麦迪逊分校 | 博士后 | | ||||||
2019-2020 | 美国亚利桑那州立大学 | 博士后 | | ||||||
学术兼职 | | | | | |||||
Frontiers in Bioengineering and Biotechnology杂志Topic Coordinator; Journal of Nanobiotechnology及Journal of Medicinal Chemistry等杂志审稿人 荣誉奖励 2024 教育部第一批博后引才专项获得者 2024 泰山学者青年专家 2023 山东省优秀青年科学基金获得者 | |||||||||
研究进展 1、天然产物是新药发现的重要来源,课题组围绕天然产物骨架进行结构修饰及活性评价,挖掘到多个活性显著,有望临床转化的小分子候选药物。首先,基于二萜类天然产物穿心莲内酯的基本骨架,构建凝血酶受体-1(PAR1)拮抗剂,筛选得到具有良好PAR1抑制活性,能够显著抑制血小板聚集、体内代谢稳定、药代动力学性质良好的候选药物(J. Med. Chem.)。第二,筛选发现三苯基磷阳离子能够携带小分子药物绕过真菌细胞外排泵的外排作用,同时有效被膜渗透,解决抗真菌药物易耐药的问题。基于此,开发得到了多个活性显著的抗真菌候选药物(Nat. Comm.)。同时,三苯基磷阳离子的化学修饰策略能够有效解决氟康唑类药物的耐药问题(Bioorg. Chem.)。第三,在异甜菊醇结构基础上,引入抗肿瘤活性基团及溶酶体靶向基团,筛选得到纳摩尔级抗肿瘤小分子且具有较高的安全性(Eur. J. Med. Chem.)。另外,以吩噻嗪结构为基础,挖掘到2个化合物的活性优于迄今为止最为有效的铁死亡抑制剂(ACS Med. Chem. Lett.)。 2、微生物是活的,可以和机体微环境相互作用。课题组基于益生菌与肠道微环境的相互作用,开发了多种膜包裹策略,增强益生菌的环境耐受性及肠道粘附力,显著增加益生菌的口服存活率及肠道滞留时间,有效提高益生菌对肠道菌群的调节能力及对肠道微环境的改善作用,提供了一种增强益生菌疾病治疗效果的有效策略,有助于推动益生菌疗法的临床转化(Sci. Adv.; Nano Today)。 | |||||||||
代表性成果 | |||||||||
代表性论文 | | | | | |||||
1. Jun Liu#, Sichen Yuan#, Alexa Bremmer, Quanyin Hu*. Convergence of Nanotechnology and Bacteriotherapy for Biomedical Applications. Advanced Science 2024, 2309295. 2. Fanyi Mo, Jun Liu*, Gang Chen*, Ningqiang Gong*, Zhaoting Li*. Nanotechnology and bioengineering platforms for drug and gene delivery. Frontiers in Bioengineering and Biotechnology 2023, 11, 1328961. 3. Jun Liu, Yixin Wang, William John Heelan, Yu Chen, Zhaoting Li, Quanyin Hu*. Mucoadhesive probiotic backpacks with ROS nano-scavengers enhance the bacteriotherapy for inflammatory bowel diseases. Science Advances 2022, 8, eabp8798. 4. Jun Liu, Wen Li, Yixin Wang, Yingyue Ding, Angela Lee, Quanyin Hu*. Biomaterials coating for on-demand bacteria delivery: selective release, adhesion, and detachment. Nano Today 2021, 41, 101291. 5. Wenqiang Chang#, Jun Liu#, Ming Zhang, Hongzhuo Shi, Sha Zheng, Xueyang Jin, Yanhui Gao, Shuqi Wang, Aiguo Ji, Hongxiang Lou*. Efflux pump-mediated resistance to antifungal compounds can be prevented by conjugation with triphenylphosphonium cation. Nature Communications 2018, 9, 1-12. 6. Jun Liu#, Bin Sun#, Xiaoyu Zhao, Jie Xing, Yanhui Gao, Wenqiang Chang, Jianbo Ji, Hongbo Zheng, Changyi Cui, Aiguo Ji*, Hongxiang Lou*. Discovery of potent orally active protease-activated receptor 1 (PAR1) antagonists based on andrographolide. Journal of Medicinal Chemistry 2017, 60, 7166-7185. 7. Jun Liu#, Lin Li#, Xiaobin Li, Xin Wang, Xiaoyu Zhao, Yanan Qiao, Yuliang Xu, Yong Sun, Lilin Qian, Zhaopeng Liu, Aiguo Ji, Hongxiang Lou*. Discovery of lysosome-targeted covalent anticancer agents based on isosteviol skeleton. European Journal of Medicinal Chemistry 2021, 209, 112896. 8. Bin Sun#, Jun Liu#, Yun Gao, Hongbo Zheng, Lin Li, Qingwen Hu, Huiqing Yuan, Hongxiang Lou*. Design, synthesis and biological evaluation of nitrogen-containing macrocyclic bisbibenzyl derivatives as potent anticancer agents by targeting the lysosome. European Journal of Medicinal Chemistry 2017, 136, 603- 618. 9. Xin Wang#, Jun Liu#, Jinyao Chen#, Ming Zhang, Chuan Tian, Xiaoping Peng, Gang Li, Wenqiang Chang*, Hongxiang Lou*. Azole-triphenylphosphonium conjugates combat antifungal resistance and alleviate the development of drug-resistance. Bioorganic Chemistry 2021, 110, 104771. 10. Jun Liu, Indrajit Bandyopadhyay, Lei Zheng, Omar M. Khdour*, Sidney M. Hecht*. Antiferroptotic activity of lipophilic phenothiazine analogues: a novel therapeutic strategy for the treatment of oxidative stress related disease. ACS Medicinal Chemistry Letter 2020, 11, 2165-2173. 11. Jun Liu, Yanling Mu, Jing Jin, Shuxiang Cui*. Effect of Sulindac on miRNA-17 and miRNA-21 Expressions in Human Colon Cancer Cells. Chin. J. Cancer Prev. Treat, 2014, 21, 485-489. 12. JunLiu, JingJin, ShuxiangCui*. Animal Models of Lung Cancer. J. Int. Oncol., 2013, 40, 758-761. 13. JunLiu, ShuxiangCui*. Animal Models of Cancer Metastasis. J. Int. Oncol., 2013, 40, 412-415. 14. Zhaoting Li, Yingyue Ding, Jun Liu, Jianxin Wang, Fanyi Mo, Yixin Wang, Ting-Jing Chen-Mayfield, Paul M. Sondel, Seungpyo Hong, Quanyin Hu*. Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment. Nature Communications 2022, 13, 1-15. 15. Zhaoting Li, Yixin Wang, Jun Liu, Piper Rawding, Jiyoon Bu, Seungpyo Hong, and Quanyin Hu*. Chemically and Biologically Engineered Bacteria Based Delivery Systems for Emerging Diagnosis and Advanced Therapy. Advanced Materials 2021, 33, 2102580. 16. Zhaoting Li, Fanyi Mo, Yixin Wang, Wen Li, Yu Chen, Jun Liu, Ting-Jing Chen-Mayfield, Quanyin Hu. Enhancing Gasdermin-induced tumor pyroptosis through preventing ESCRT-dependent cell membrane repair augments antitumor immune response. Nature Communications, 2022, 13, 6321. 17. Changyi Cui, Jun Liu, HongBo Zheng, Xue-Yang Jin, Xiao-Yu Zhao, Wen-Qiang Chang, Bin Sun, Hongxiang Lou*. Diversity-oriented Synthesis of Pyrazoles Derivatives from Flavones and Isoflavones Leads to the Discovery of Promising Reversal Agents of Fluconazole Resistance in Candida Albicans. Bioorg. Med. Chem. Lett., 2018, 28, 1545- 1549. 18. Xiaoyu Zhao, Bin Sun, Hongbo Zheng, Jun Liu,Lilin Qian, Xiaoning Wang, Hongxiang Lou*. Synthesis and Biological Evaluation of 6-Hydroxyl C-aryl Glucoside Derivatives as Novel Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors. Bioorg. Med. Chem. Lett., 2018, 28, 2201-2205. 19. Jinchuan Zhou, Jiaozhen Zhang, Ruijuan Li, Jun Liu, Peihong Fan, Yi Li, Mei Ji, Yiwen Dong, Huiqing Yuan, Hongxiang Lou*. Hapmnioides A-C, Rearranged Labdane-Type Diterpenoids from the Chinese Liverwort Haplomitrium mnioides. Org. Lett., 2016, 18, 4274-4276. | |||||||||
专利 | | | | | |||||
1. 娄红祥,刘军,孙斌,异舔菊醇衍生物的制备方法及应用, 2020.5,ZL201810106694.5,中国 2. 娄红祥,刘军,孙斌,甜菊醇衍生物的制备方法及应用,2019.12, ZL201810107228.9,中国 3. Quanyin Hu, Jun Liu. Mucoadhesive probiotic backpacks with ROS nano-scavengers enhance the bacteriotherapy for inflammatory bowel diseases,P220262US01,美国 4. Quanyin Hu, Jun Liu. Biomaterials coating for on-demand bacteria delivery and method to treat colitis and irritable bowel syndrome,P210279US01,美国 5. Hongxiang Lou, Bin Sun, Jun Liu, PAR1 inhibitor based on terpene derivative and preparation method and use in treatment of thrombotic diseases thereof,2017.6,PCT/CN2016/070851,WIPO 6. Omar Khdour, Sidney Hecht, Jun Liu, Indrajit Bandyopadhyay, Mitochondrial therapeutic agents, 2021-9-14,PCT/US21/50306,WIPO 7. 娄红祥,王鑫,刘军,一种三氮唑类化合物、制备方法及其在抗真菌药物中的应用,2023.2,ZL202010707336.7,中国 8. 娄红祥,孙斌,刘军,基于萜类衍生物的PAR-1抑制剂及其制备方法和在治疗血栓性疾病中的用途,2018.8,ZL201510975205.6,中国 | |||||||||
| | | | ||||||
项目课题 | |||||||||
1. 国家自然科学基金面上项目,2024-2027,主持 2. 教育部博后引才专项,2024-2026,主持 3. 泰山学者青年专家项目,2024-2026,主持 4. 山东省优秀青年科学基金,2023-2025,主持 5. 350vip8888新葡的京集团“青年英才工程”第一层次启动经费,2023-2027,主持 6. 青岛海洋科学与技术国家实验室创新人才引进项目,2023-2027,主持 7. 国家自然科学基金青年基金,2021-2023,主持 8. 山东省自然科学基金博士基金,2019-2022,主持 9. 国家自然科学基金面上项目(81874293),2019-2022,参与,57万元 10. 国家自然科学基金面上项目(81773786),2018-2021,参与,59.5万元 | |||||||||
【关闭】